Welcome to our dedicated page for Twist Bioscience SEC filings (Ticker: TWST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Twist Bioscience's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Twist Bioscience's regulatory disclosures and financial reporting.
Robert F. Werner, Chief Accounting Officer and director of Twist Bioscience Corp (TWST), reported a non-discretionary sale of 2,041 shares of common stock on 10/06/2025 at a price of $32.187 per share. After the sale, Mr. Werner beneficially owned 46,413 shares. The filing states the shares were sold to satisfy tax-withholding obligations tied to the vesting of Performance Stock Units (PSUs) and were executed under the issuer's mandatory "sell to cover" election, not as voluntary open-market trades. The Form 4 was signed by an attorney-in-fact on 10/08/2025.
Paula Green, Senior Vice President of Human Resources at Twist Bioscience Corp (TWST), reported a non‑discretionary sale of 9,724 common shares on 10/06/2025 at an effective price of $32.187 per share to satisfy tax withholding tied to vested Performance Stock Units (PSUs).
After the sell‑to‑cover, the reporting person beneficially owns 114,678 shares. The filing was submitted under Form 4 and signed by an attorney‑in‑fact on 10/08/2025. The sale was mandated by the issuer's equity plan election and is described as not a discretionary trade.
Insider sale to cover taxes: The Form 4 shows that Patrick John Finn, President and COO of Twist Bioscience Corp (TWST), had 23,747 shares of common stock sold on 10/06/2025 at $32.187 per share. The filing states these sales were mandatory "sell to cover" transactions to meet tax‑withholding obligations tied to vested Performance Stock Units (PSUs) and were not discretionary trades. After the transaction, the reporting person beneficially owned 208,735 shares. The sale was reported on 10/08/2025 and signed by an attorney‑in‑fact.
Twist Bioscience Corp (TWST) reported an insider sale by Dennis Cho, Senior Vice President, Chief Legal Officer & Corporate Secretary. On 10/06/2025 Mr. Cho sold 3,876 shares of common stock at a price of $32.187 per share to satisfy tax withholding tied to the vesting of Performance Stock Units (PSUs). After the transaction he beneficially owned 98,710 shares. The filing notes these were mandatory "sell to cover" transactions elected under the company equity plans and are not discretionary trades by the reporting person.
Twist Bioscience Corp (TWST) insider filing reports a proposed sale of 3,000 common shares through Fidelity Brokerage Services LLC with an aggregate market value of $93,450, and an approximate sale date of 10/08/2025 on NASDAQ. The shares were acquired on 10/01/2025 via restricted stock vesting and were paid as compensation. The filer also disclosed three prior open-market sales during the past three months totaling 9,242 shares for gross proceeds of $306,353.08 (sales on 07/09/2025, 08/21/2025, and 10/06/2025). The notice includes the standard representation that the seller is unaware of undisclosed material adverse information.
Artisan Partners group reported beneficial ownership of 6,410,900 shares of Twist Bioscience Corporation common stock, representing 10.6% of the outstanding class based on 07/30/2025 share count. The filing shows no sole voting or dispositive power; instead the filers report shared voting power of 5,303,412 shares and shared dispositive power of 6,410,900. The shares are held for discretionary clients of Artisan Partners Limited Partnership and, according to the certification, were acquired in the ordinary course of business and not with the purpose of changing control. The report is filed as a joint Schedule 13G amendment and includes a joint filing agreement signed on 10/07/2025.
Insider sale notice: A Form 144 was filed indicating a proposed sale of 5,875 common shares of Twist Bioscience Corp (TWST) with an aggregate market value of $189,098.63. The shares were acquired on 10/01/2025 via restricted stock vesting and the filing lists an approximate sale date of 10/06/2025 on NASDAQ. The filing reports 60,360,925 shares outstanding, making the proposed block roughly 0.0097% of the outstanding shares. The filer previously sold 2,449 shares on 07/09/2025 for $93,419.31 and 918 shares on 08/21/2025 for $23,835.14. The acquisition was recorded as compensation on 10/01/2025. The filer certifies no undisclosed material adverse information.
Form 144 notice shows an insider proposes to sell 31,348 shares of common stock, with an aggregate market value of $1,008,998.08, representing approximately 0.052% of the 60,360,925 shares outstanding. The shares were acquired through restricted stock vesting on 10/01/2025 and the approximate sale date is 10/06/2025. The filing lists prior insider sales in the past three months totaling 12,746 shares for gross proceeds of $348,121.10, with individual sale dates between 08/04/2025 and 10/02/2025. The filer attests there is no undisclosed material adverse information and notes the securities were received as compensation.
Twist Bioscience Corp (TWST) submitted a Form 144 notice reporting a proposed sale of 2,041 common shares with an aggregate market value of $65,693.67, planned for 10/06/2025 on NASDAQ. The shares were acquired on 10/01/2025 through restricted stock vesting and the stated nature of payment is compensation. The filer also disclosed four earlier open-market sales by the same person between 08/04/2025 and 09/08/2025, totaling 1,511 shares and gross proceeds of $41,029.46. The notice includes the usual representation that the seller is not aware of undisclosed material adverse information.
Twist Bioscience Corp (TWST) filed a Form 144 reporting a proposed sale of 23,747 common shares with an aggregate market value of $764,344.69, representing part of shares acquired by restricted stock vesting on 10/01/2025. The filing lists the intended approximate sale date as 10/06/2025 on NASDAQ. It also discloses recent insider sales by Patrick Finn totaling 7,467 shares across 07/23/2025, 08/04/2025, 08/21/2025, and 10/02/2025 with combined gross proceeds visible in the table. The filer contact and CIK fields appear incomplete in the form, and no earnings or corporate operational details are included.